🧬 Bio-Infra Landscape 2025

Building on the foundation laid by Ada Ventures’ Bio-Infrastructure thesis (S/O Francesca (Check) Warner and Mills & Reeve), we’ve expanded the landscape using Specter — mapping 500+ companies powering the underlying stack for next-generation healthcare. This includes lab automation, AI-native patient data platforms, scalable biomanufacturing, regulatory infrastructure, and workforce tooling.

As healthcare moves from episodic care to continuous, preventative systems, these companies are laying down the rails — enabling real-time diagnostics, AI-driven clinical workflows, and resilient bio-supply chains. This is the emerging operating system for the 100-year life: proactive, personalized, and built to scale.

This is the definitive market map of how Bio-Infrastructure is re-architecting the future of health.

Get The Bio-Infra Landscape!

Already a Specter user? Click here to explore the Bio-Infra Landscape Landscape 🚀
Not on Specter yet? Download the list and get in touch to access the full dataset 📥

Download

Bio-Manufacturing

Caladan Bio (🌟 Specter - Global Rank 1,462)
Brooklyn-based Caladan Bio is building low-cost, sensor-rich benchtop bioreactors to generate AI-ready data for strain-optimisation. Feb 2024 the startup closed a $5.1m seed round led by Twelve Below with Collaborative Fund, Lerer Hippeau, Wireframe Ventures, Ritual Capital and Factorial joining. Founders Mike Kobida and Rob Jauquet are hiring firmware and data-science talent to scale pilot installations of the 24-reactor “Caladan 250”, which early users report cuts bioprocess-development time by ~50%‍. NYC-based, Caladan aims to become the instrumentation backbone of next-gen biomanufacturing.

Nuclera (🌟 Specter - Global Rank 273,213)
Cambridge- and Boston-based Nuclera’s eProtein Discovery™ system unites digital microfluidics with cell-free synthesis to deliver milligram-scale proteins in <48 h. A $75m series c on Oct 2024 led by Elevage Medical Technologies lifted total funding to ≈$145.8m. Founders Michael Chen (CEO) and Jiahao Huang are doubling head-count as they expand US/EU rollout. In May 2025 Nuclera teamed with Cytiva to link its instrument to Biacore™ SPR—promising “protein-to-characterisation in five days” for drug-discovery teams‍. Installations now span CROs and leading universities.

AIBioTech (🌟 Specter - Global Rank 99,209)
Offers integrated molecular, immuno- and bio-analytical services from a 32,000 sq ft lab. The company has raised a modest $1m to date, last recorded on Nov 2016 (series unknown)‍ and continues to self-fund expansion. Core capabilities span pharmacogenetic panels, virology, peptide chemistry and clinical assay validation‍. Historic wins include a $21m federal contract for specialised testing services‍. AIBioTech’s ~75-person team emphasises rapid, end-to-end assay development for pharma and government clients.

Immunologix Laboratories (🌟 Specter - Global Rank 401,703)
Tampa-headquartered Immunologix is a GLP/GCP bioanalytical lab specialising in ligand-binding, cell-based and qPCR assays for biologics and gene-therapy programs. Entirely bootstrapped, the lab earned nationwide CLIA certification in Feb 2024, enabling high-complexity LDTs for patient-specific trial decisions‍. Its Translational Sciences division, launched 2019, gives clients strategic biomarker and PK-immunogenicity support through all development stages‍. Immunologix reports sub-picogram sensitivity in immunogenicity workflows and sustained double-digit web-traffic growth.

Lab Automation

Benchling (🌟 Specter - Global Rank 385 629)
Benchling’s cloud-native R&D platform is now used by 1,200-plus biotech and pharma companies and 200k+ scientists to centralise data and automate lab workflows. Founded in 2012 by MIT classmates Sajith Wickramasekara and Ashu Singhal, the SF-based company is classed Late-Stage and has raised US $411.9m in total, most recently a US $100m series f on Nov 2021 co-led by Altimeter Capital and Franklin Templeton at a US $6.1bn valuation. May 2025 brought an AI-ready research collaboration with Moderna that puts hundreds of scientists on a unified Benchling instance, while the new “AI at Benchling” tool-set lets users build models without code. Key backers include Alkeon Capital, Altimeter Capital and Andreessen Horowitz.

Scispot (🌟 Specter - Global Rank 1,621)
Scispot is an AI-powered, API-first platform that unifies experiment planning, execution and data management for life-science labs. The company was founded in 2020 by molecular-biologist-turned-entrepreneur Guru Singh and product veteran Satya Singh. Now at Pre-seed / Seed stage, it has raised ≈ $1.7m (latest $1.2m seed round, Oct 2023) from Pipefish Ventures, Kindred Capital and others, and in May 2025 joined Y Combinator’s growth program. June 2025 saw the launch of an AI analytics module that lets scientists build dashboards via natural-language prompts, and the firm is currently hiring a Principal AI/Full-Stack Engineer. HQ-ed in Kitchener, Ontario, Scispot reports strong user-growth and remains capital-efficient.

Automata (🌟 Specter - Global Rank 383,726)
London-based Automata builds LINQ—an open, integrated robotics bench that digitises end-to-end lab workflows. Founded by architects-turned-roboticists Mostafa ElSayed and Suryansh Chandra, the company has attracted Dimension, A.P. Moller Holding, Octopus Ventures and ABB Ventures, amassing ≈ $100m in total funding. Its most recent raise was a $40m series b in October 2023. Over 2024 – 25 Automata rolled out an upgraded LINQ platform and opened a Boston hub to support U.S. expansion, while continuing to hire in robotics, cloud and field-engineering.

DP Technology (🌟 Specter - Global Rank 385,527)
Beijing’s DP Technology applies “AI for Science” models—Uni-Mol, Uni-Fold and others—to drug discovery, battery chemistry and materials design. Founded in 2018 by physicists Weijie Sun (CEO) and Linfeng Zhang (CSO), the late-stage venture has raised ≈ $140m to date, including a ~$100m round disclosed in Aug 2023 and “hundreds of millions RMB” follow-on capital co-led by Qiming Venture Partners in 2024. At its April 2024 DevDay the firm unveiled DPA and Uni-SMART large science models and launched an Open-Science initiative. Headcount is scaling fast as DP courts Western pharma clients.

Patient Data

Ultragenic (🌟 Specter - Global Rank 382,098)
Cloud-based pharmacovigilance analytics and data-migration suites (UltraPaaS & UltraAnalytics) help pharma teams automate case intake and generate regulatory-grade safety reports. Founded by Pravin Nath, Amit Jain, Mayank Bhandari and Saurabh Singh. Bootstrapped (no external investors, funding undisclosed); no recorded institutional raise to date. Highlights include Headcount Surge & Momentum plus Web-traffic growth. Based in Delhi, India. Recent launches of UltraPaaS (May 2025) and AI-driven UltraAnalytics dashboards have spelled tail-wind for operations and underpinned EU expansion push.

Embleema (🌟 Specter - Global Rank 5,455)
Platform unifying clinical, molecular and real-world patient data to accelerate precision-medicine studies and return data ownership to participants. Founded by Robert Chu. Pre-seed/Seed stage, backed by Pharmagest, MassChallenge and Techstars with total funding of $4m; last raise on Dec 2019 (non-equity assistance). Highlights include Headcount Surge & Momentum, App-download growth, Web-traffic momentum. HQ-ed in NYC, USA. In June 2025 Embleema joined AARP’s AgeTech Collaborative, piloting data-collection protocols for 50-plus populations; its FDA-validated blockchain network now spans more than 60,000 care sites, enabling tokenised patient consent at scale.

ekincare (🌟 Specter - Global Rank 10,262)
AI-powered health-benefits platform combining tele-medicine, preventive screenings and pharmacy services for employees. Founded by Kiran Kalakuntla, Srikanth Samudrala and Noel Coutinho. Growth stage backed by HealthQuad, MSD IDEA Studio and others with total funding of $21m; last raise on Apr 2025 (series c, amount undisclosed). Highlights: Headcount Surge, Momentum & Scale-up; Web-traffic surge & momentum. HQ: Hyderabad, India.

Abridge (🌟 Specter - Global Rank 61,186)
Ambient-AI platform that converts patient-clinician conversations into structured, billable notes integrated with Epic. Founded by Shivdev Rao, Florian Metze and Sandeep Konam. Late stage backed by Andreessen Horowitz, Khosla Ventures, UPMC and others with total funding of $757.5m; last raise $300m on June 2025 (series e). Highlights: Headcount Surge, Momentum & Scale-up; Web-traffic surge & momentum. HQ: Pittsburgh, USA. The June 2025 series e valued Abridge at $5.3bn and fuels rollout to 150+ health-systems; new inpatient modules and nurse-workflow pilots with Mayo Clinic target processing 50m clinical conversations in 2025.

Reg-tech

SimplerQMS (🌟 Specter - Global Rank 53,325)
SimplerQMS delivers a fully-validated, cloud-based eQMS that helps life-science firms automate document control, change-management and training workflows, staying audit-ready under ISO 13485 and FDA 21 CFR Part 820. Bootstrapped since its 2017 launch by Danish founders Allan Murphy Bruun and Jacob Sjørslev Hyrdum, the company raised its first outside capital in April 2025—€4 million (~$4.3m) from EIFO Denmark and life-science angels—to expand product R&D and launch a Quality Academy. Backed by EIFO Denmark, angel syndicate. Total funding: ~$4.3m. Last round: Apr 2025 – angel. Highlights include Headcount Surge, Social Followers Momentum. HQ-ed in Copenhagen, Denmark.

Aclid (🌟 Specter - Global Rank 62,124)
Aclid automates biosecurity and export-control screening for DNA/RNA synthesis orders, letting gene- and oligo-foundries stay compliant in seconds rather than hours. Co-founders Kevin Flyangolts (ex-Bloomberg/IAC) and Columbia professor Harris H. Wang closed an oversubscribed $3.3m seed round on Oct 2023, led by 2048 Ventures and IA Ventures, their only funding to date. Pre-seed / Seed backed by 2048 Ventures, IA Ventures. Total funding: $3.3m. Last round: Oct 2023 – seed. Recently high Social Followers Momentum. HQ: New York City, USA.

Nym (🌟 Specter - Global Rank 265,835)
Nym’s Clinical Language Understanding engine turns physician notes into fully audited CPT/ICD-10 codes with >95% accuracy, cutting claim-submission time by half. On Oct 2024 the New York/Tel-Aviv company secured a $47m growth investment led by PSG with GV, Addition and Tiger Global joining, bringing total funding to ~$94.5m. Founders Amihai Neiderman and Adam Rimon are scaling multi-specialty coverage and hiring clinical-AI engineers. Growth Stage backed by PSG, GV, Addition, Tiger Global, Bessemer. Total funding: $94.5m. Last round: Oct 2024 – Growth equity. HQ: New York City, USA.

Within3 (🌟 Specter - Global Rank 389,788)
Within3’s asynchronous insights-management platform lets medical-affairs and clinical-teams run virtual advisory boards and stakeholder engagements, claiming 100% KOL participation across 150 countries. CEO Lance P. Hill has led the Ohio-based firm since 2007; its $100m+ growth round on 24 Sep 2020, led by Insight Partners with Silversmith Capital, funds AI-powered analytics and APAC expansion. Late Stage backed by Insight Partners, Silversmith Capital, Easton Capital, Drummond Road. Total funding: $120m. Last round: Sep 2020 – Private Equity. Highlights include Top-tier investors and broad pharma adoption. HQ: Lakewood, Ohio, USA.

Talent + Workforce

Drug Hunter (🌟 Specter - Global Rank 415,127)
Drug Hunter, founded in 2018 by biotech scientist Dennis X. Hu, is a bootstrapped digital knowledge platform delivering deep-dive content, newsletters, and Flash Talk videos for drug discovery professionals. In January 2025, its “Year 8” report highlighted the expansion of its Flash Talk series—hosting leading scientists—and a 30% surge in subscriber growth, reinforcing its mission to unite R&D experts through rapid, community-driven insights. Under Hu’s leadership, the Greater Boston–based team recently added a Head of Industry Research to spearhead partnerships, even as the platform remains entirely self-funded with no external rounds. Drug Hunter boasts 22K+ LinkedIn followers and continues to show strong website traffic and social-followers momentum. Based in Greater Boston, Massachusetts, United States.

Peerr (🌟 Specter - Global Rank 81,175)
Peerr is a pre-seed professional networking platform (May 7, 2024, Pre Seed round, $145,000) for health and life-sciences experts to connect, share paid mentoring channels, and monetize insights. Co-founded in 2021 by Dr Abdul Rahyead and Dr Ahamodur Choudhury, Peerr was selected as one of 10 Forum Ventures–backed startups, celebrating over 1m content engagements across 180+ countries—features aimed at reshaping collaboration through AI-powered, ring-fenced communities. The London-based team is now building a WhatsApp-integrated extension, preparing to launch paid audio-learning in 2025. Investors include Forum Ventures and Right Side Capital Management. Based in London, England, United Kingdom.

CareRev (🌟 Specter - Global Rank 380,905)
An on-demand workforce marketplace for acute care, empowering 35,000+ healthcare professionals to book shifts in real time via its app. On June 2025, it expanded to support allied and ancillary roles—such as physical and occupational therapists—through its Internal Resource Pool Plus (IRP+) tech, offering predictive analytics and in-app notifications to fill last-minute staffing gaps. Led by CEO Brandon Atkinson, the Los Angeles team recently added Larry Adams as Chief Nurse Executive. With $56.5m raised (series unknown on July 2025) from Transformation Capital, Tribe Capital, Y Combinator, Zach Coelius and others, CareRev combines AI-driven scheduling with strong headcount and app-download momentum. Based in Los Angeles, California, United States.

Scientist.com (🌟 Specter - Global Rank 675,975)
Scientist.com’s AI-powered research marketplace and white-glove Research Concierge® services connect buyers with 5,000+ CROs. In mid-2025 it launched Procurement CoPilot™, a GenAI assistant that automates supplier sourcing and guided buying, streamlining compliance and workflow orchestration. Co-founded in 2007 by Kevin Lustig, Chris Petersen, and Andrew Martin, CEO Kevin Lustig has expanded private-marketplace offerings for enterprise clients and scaled the Solana Beach office. With $5.5m in debt financing on December 9, 2022, backed by 5AM Ventures, Bootstrap Ventures, and Leerink Transformation Partners, Scientist.com has facilitated over $1bn in service transactions and maintains strong web-traffic momentum. Based in Solana Beach, California, United States.

Strategic Outlook

Bio-manufacturing is atomising. Benchtop “micro-reactors” from Caladan Bio and cell-free platforms like Nuclera now plug into lab software via simple APIs, while AI-first lab OSes (Scispot) and modular robots (Automata LINQ) snap into existing benches. Even diagnostics giant CorDx sells TyFast™ assays as drop-in components. Vector databases knit omics, reactor and clinical-note data together for real-time strain ranking, assay scheduling and QC—without breaching HIPAA or GxP walls.

Stacks are forming along the entire pipeline. Upstream tools (Caladan, Nuclera) compress protein or lipid iteration from weeks to days; lab-automation layers (Scispot, Automata) turn raw data into structured ELN/LIMS records; “AI-for-Science” engines (DP Technology) skip wet-lab steps with large molecular models; downstream compliance (SimplerQMS, Aclid, Nym) embeds eQMS and export-control checks directly into production.

Capital is surging. Since 2023, > US $1.5bn has flowed into lab-automation, diagnostics and clinical-workflow players. Big rounds—Nuclera’s US $75m series c (2024) and Abridge’s US $300m series e (2025)—sit alongside sizeable contracts such as CorDx’s US $86m HHS award. Seed appetite remains high (Caladan US $5.1m, Aclid US $3.3m).

What’s next? Shared bio-knowledge graphs, federated fine-tuning, and mandatory AI-governance layers will define the secure, always-on operating stack for tomorrow’s adaptive biomanufacturing and healthcare services.

Key Takeaways

Purpose-built lab-AI “co-pilots” are eclipsing generic LIMS add-ons. Sensor-rich bioreactors from Caladan Bio and microfluidic eProtein workstations from Nuclera let scientists generate model-ready data in hours, while Scispot’s API-first ELN/LIMS and Automata’s LINQ robotics bench automate every pipette step—far outpacing bolt-on GenAI widgets in legacy systems.
Privacy-by-design compliance fabrics are now table-stakes. CLIA-certified Immunologix Labs, ISO 13485-validated SimplerQMS and EUA-cleared diagnostics maker CorDx keep sensitive samples and documents inside jurisdiction-bound “lab data spaces,” pairing audit-grade chains-of-custody with federated-learning dashboards for GxP, GDPR and Part 11 peace of mind.
Vertical, end-to-end stacks shorten sales cycles. Nuclera’s May-2025 tie-up with Cytiva links rapid protein synthesis to Biacore™ characterisation; Automata sells a full robotics-plus-software bench; and CROs such as AIBioTech bundle assay development, validation and reporting—letting customers activate multiple workflows on day one and expand wallet share over time.
Open-API and hardware–software interoperability standards loom large. Buyers now expect best-of-breed modules—experiment design (Scispot), robotics (Automata), procurement (Scientist.com)—to plug into any data backbone, mirroring ISO-style schemas spreading from finance into the lab.
Compliance-first positioning is a widening moat. Vendors that foreground traceable AI and export-control screening (Aclid), explainable coding engines (Nym) or quality-document validation (SimplerQMS) consistently outflank rivals still pitching pure productivity gains.
Seed cheques have settled in the $3m–$6m band. Caladan Bio’s $5.1m seed (Feb 2024) and Aclid’s $3.3m seed (Oct 2023) typify the new normal, while growth capital stretches to Nuclera’s $75m series c and Abridge’s $300m series e.
Bootstrapped outliers still chart viable paths. Diagnostics giant CorDx, assay specialist Immunologix Labs, CRO AIBioTech and knowledge-platform Drug Hunter keep compounding on customer revenue before courting VC—echoing Spellbook-style traction pre-series a.
The talent war intensifies. Engineers exiting DeepMind-calibre labs flock to Scispot and DP Technology; hardware veterans join Caladan and Automata; healthcare operators converge on CareRev—transplanting hard-won expertise in AI ops, robotics and staffing optimisation into these scaling startups.